Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
– Results support advancement of 10 mg dose into Phase 3 development –– End-of-Phase 2 meeting request accepted by U.S. FDA; pa...
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiv...
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the Decem...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the presentation of clinical data from the company's Phase 2b P...
Presentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic per...
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the Decem...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Company will present new data demonstrating the reduction ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...
